Class Cert. Denied In Pfizer Pay-For-Delay Suit

Law360, Los Angeles (January 30, 2014, 10:18 PM EST) -- A Tennessee federal judge on Thursday refused to grant class certifications to two groups claiming Pfizer Inc.’s King Pharmaceuticals Inc. settled a patent dispute with a deal to keep muscle relaxant Skelaxin off the market in a pay-for-delay arrangement that kept the drug prices at brand-name levels.

U.S. District Judge Curtis L. Collier shut down the bids of a group of end payors and a group of indirect purchasers who argued they, as classes, were wronged by the drugmakers in the patent dispute because the deal...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.